Last Updated : April 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| N/A | everolimus | Tuberous Sclerosis Complex (TSC) | Active | |||
| TBC | cabotegravir | HIV-1 infection, pre-exposure prophylaxis | Active | |||
| N/A | mepolizumab | Eosinophilic Granulomatosis with Polyangiitis | Active | |||
| N/A | Nab-paclitaxel | Gastrointestinal cancer | Active | |||
| Truqap | capivasertib | HR-positive, HER2-negative locally advanced or metastatic breast cancer | Active | |||
| Treanda (in combination with rituximab) | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia | Withdrawn | |||
| Prevymis | letermovir | Cytomegalovirus infection (CMV), prophylaxis | Active | |||
| TBC | lebrikizumab | atopic dermatitis | Active | |||
| Opdivo | nivolumab | Stage IIB or IIC melanoma, adjuvant | Active | |||
| Leqvio | inclisiran | Primary hypercholesterolemia | Active |
Last Updated : April 20, 2024